多药耐药蛋白和CYP3A4介导的中草药-西药相互作用

摘要/Abstract

摘要： 据近年的流行病学报告, 国内外越来越多的人终身服用各种中草药, 包括各类疾病患者(如:癌症等)和健康人群。随着中草药与处方西药联合应用治疗疾病的日益增多, 越来越多的人注意到这两者的同时使用可能引起的中草药-西药相互作用会影响到治疗药物的活性。目前已知P-糖蛋白(P-gp)和CYP3A4 一起能构成许多口服吸收药物的高效屏障, 然而50%以上的临床用药都会被CYP3A4 代谢或被P-gp 转运。本文综述了多药耐药蛋白和CYP3A4 介导的中草药-西药相互作用, 同时也讨论了中草药-西药相互作用的关键因素。

关键词: P-糖蛋白, CYP3A4, 处方西药, 中草药, 生物利用度

Abstract: According to recent epidemiological reports more and more people, both healthy and ill, use all kinds of Chinese herbal medicine during their lifetime.As the increasing combined usage of Chinese herbal medicine with prescription drugs, it draws lots of attentions on the therapeutic activity due to possible drug-herb interaction. It is known that P-glycoprotein (P-gp)together with cytochrome P450 3A4 (CYP3A4)leads to a highly efficient barrier for many orally absorbed drugs.Meanwhile, more than 50% of the clinical drugs are metabolized by CYP3A4 or transported by P-gp.Hence, more attention should be paid to MDR-and CYP3A4-mediated drug-herbal interactions.This survey discusses the key-factors of drug-herbal interaction as well.

Key words: P-glycoprotein, CYP3A4, prescribed drug, herb, bioavailability

中图分类号:

R968
R969

毛晓琴, 谢海棠, 周宏灏. 多药耐药蛋白和CYP3A4介导的中草药-西药相互作用[J]. 中国临床药理学与治疗学, 2007, 12(7): 728-734.

MAO Xiao-qin, XIE Hai-tang, ZHOU Hong-hao. MDR-and CYP3A4-mediated drug-herbal interactions[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2007, 12(7): 728-734.

参考文献

1 Sparreboom A, Danesi R, Ando Y, et al.Pharmacogenomics of ABC transporters and its role in cancer chemotherapy[J].Drug Resist Updat, 2003;6:71-84.
2 Thiebaut F, Tsuruo T, Hamada H, et al.Cellular localization of the multidrug resistance gene product P-gly coprotein in normal human tissues[J].Proc Natl Acad Sci USA, 1987;84:7735-7738.
3 de Lannoy IA, SilvermanM.TheMDR1 gene product P-gly coprotein, mediates the transport of the cardiac gly coside, digoxin [J].Biochem Biophys Res Commun, 1992;189:551-557.
4 Fromm MF.P-glycoprotein:a defense mechanism limiting oral bioavailability and CNS accumulation of drugs[J].Int J Clin Pharmacol Ther, 2000;38:69-74.
5 Sakaeda T, Nakamura T, Okumura K.MDR1 genotype-related pharmacokinetics and pharmacodynamics[J].Biol Pharm Bull, 2002;25:1291-1400.
6 Kim RB, Fromm MF, Christoph W, et al.The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV21 protease inhibitors[J].J Clin Invest, 1998;101:289-294.
7 Bosch I, Croop J.P-glycoprotein, multidrug resistance and cancer[J].Biochim Biophys Acta, 1996;1288:F37-F54.
8 Borst P, Evers R, Kool M, et al.A family of drug transporters:the multidrug resistance-associated proteins[J].J Natl Cancer Inst, 2000;92:1295-1302.
9 Hyde SC, Emsley P, HartshornMJ, et al.Structural model of ATP-binding proteins associated with cystic fibrosis, multidrug resistance and bacterial transport[J].Nature, 1990;346:362-365.
10 Ambudkar SV, Dey S, Hry cyna CA, et al.Biochemical, cellular, and pharmacological aspects of the multidrug transporter [J].Annu Rev Pharmacol Toxicol, 1999;39:361-398.
11 Lin JH, Yamazaki M.Role of P-glycoprotein in pharmacokinetics: clinical implications[J].Clin Pharmacokinet, 2003;42:59-98.
12 Yu DK.The contribution of P-glycoprotein to pharmacokinetic drug-drug interactions[J].J Clin Pharmacol, 1999;39:1203-1211.
13 Chiou WL, Chung SM, Wu TC.Potential role of P-glycoprotein in affecting hepatic metabolism of drugs[J].Pharm Res, 2000; 17:903-905.
14 Katoh M, Nakajima M, Yamazaki H, et al.Inhibitory effects of CYP3A4 substrates and their metabolites on P-glycoproteinmediated transport[J].Eur J Pharm Sci, 2001;12:505-513.
15 Wacher VJ, Salphati L, Benet LZ, et al.Active secretion and enterocytic drug metabolism barriers to drug absorption[J].Adv Drug Deliv Rev, 2001;46:89-102.
16 Weinstein RS, Kuszak JR, Kluskens LF, et al.P-glycoproteins in pathology:the multidrug resistance gene family in humans[J].Hum Pathol, 1990;21:34-48.
17 朱冰.3A 的分子机制研究[J].中国药理学通报, 2000; 16:614-617.
18 Patel J, Mitra AK.Strategies to overcome simultaneous P-glycoprotein mediatedefflux and CYP3A4 mediated metabolism of drugs[J].Pharmacogenomics, 2001;2:401-415.
19 Relling MV.Are the major effects of P-glycoprotein modulators due to altered pharmacokinetics of anticancer drugs[J]? Ther Drug Monit, 1996;18:350-356.
20 Slaughter RL, Edwards DJ.Recent advances:the cytochrome P-450 enzymes[J].Ann Pharmacother, 1995;29:619-624.
21 Schuetz EG, Beck WT, Schuetz JD.Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells[J].Mol Pharmacol, 1996;49:311-318.
22 Gallicano K, Foster B, Choudhri S.Effect of short-term administration of garlic supplements on single-dose ritonavir pharmacokinetics in healthy volunteers[J].Br J Clin Pharmacol, 2003; 55:199-202.
23 Piscitelli SC, Burstein AH, Welden N, et al.The effect of garlic supplements on the pharmacokinetics of saquinavir[J]. Clin Infect Dis, 2002;34:234-238.
24 Hsu A, Granneman GR, Bertz RJ.Ritonavir.Clinical pharmacokinetics and interactions with other anti-HIV agents[J].Clin Pharmacokinet, 1998;35:275-291.
25 Brinker F.Herb Contraindications and Drug Interactions[M]. Sandy, Oregan:Eclectic Medical Publications, 1998.
26 Izzo AA, Ernst E.Interactions between herbal medicines and prescribed drugs:a systematic review[J].Drugs, 2001;61: 2163-2175.
27 Moore LB, Goodwin B, Jones SA, et al.St.John's wort induces hepatic drug metabolism through activation of the pregnane X receptor[J].Proc Natl Acad Sci USA, 2000;97:7500-7502.
28 Durr D, Stieger B, Kullak-Ublick GA, et al.St.John's wort induces intestinal P-glycoprotein MDR1 and intestinal and hepatic CYP3A4[J].Clin Pharmacol Ther, 2000;68:598-604.
29 Perloff MD, von Moltke LL, Stormer E, et al.Saint John's wort:an in vitro analysis of P-gly coprotein induction due to extended exposure[J].Br J Pharmacol, 2001;134:1601-1608.
30 Bistrup C, Nielsen FT, Jeppesen UE, et al.Effect of grapefruit juice on Sandimmun Neoral absorption among stable renal allograft recipients[J].Nephrol Dial Transplant, 2001;16:373-377.
31 Soldner A, Christians U, Susanto M, et al.Grapefruit juice activates P-glycoprotein-mediated drug transport [J].Pharm Res, 1999;16:478-485.
32 Bailey DG, Malcolm J, Arnold O, et al.Grapefruit juice-drug interactions[J].Br J Clin Pharmacol, 1998;46:101-110.
33 Liao BS, Newmark H, Zhou RP.Neuroprotective effects of ginseng totalsaponin and ginsenosides Rb1 and Rg1 on spinal cord neurons in vitro[J].Exp Neurol, 2002;173:224-234.
34 Park JD, Kim DS, Kwon HY, et al.Effects of ginseng saponin on modulation of multidrug resistance[J].Arch Pharm Res, 1996;19:213-218.
35 Kim SW, Kwon HY, Chi DW, et al.Reversal of P-glycoprotein-mediated multidrug resistance by ginsenosideRg(3)[J]. Biochem Pharmacol, 2003;65:75-82.
36 Harkey MR, Henderson GL, Gershwin ME, et al.Variability in commercial ginseng products:An analysis of 25 preparations [J].Am J Clin Nutr, 2001;73:1101-1106.
37 Ammon HPT, WahlMA.Pharmacology of Curcuma longa[J]. Planta Med, 1991;57:1-7.
38 Anuchapreeda S, Leechanachai P, Smith MM, et al.Modulation of P-gly coprotein expression and function by curcumin in multidrug-resistant human KB cells[J].Biochem Pharmacol, 2002;64:573-582.
39 Smith M, Lin KM, Zheng YP.An open trial of nifedipine-herb interactions:Nifedipine with St.John's wort, ginseng or Ginkgo biloba[J].Clin Pharmacol Ther, 2001;69:P86.
40 Chavez ML, Chavez PI.Ginkgo (part 1):history, use, and pharmacologic properties[J].Hosp Pharm, 1998;33:658-672.
41 Rosenblatt M, Mindel J.Spontaneous hyphema associated with ingestion of Ginkgobiloba extract[J].N Engl J Med, 1997; 336:1108.
42 Piscitelli SC, Formentini E, Burstein AH, et al.Effect of milk thistle on the pharmacokinetics of indinavir in healthy volunteers [J].Pharmacotherapy, 2002;22:551-556.
43 Brinker F.Herb Contraindications and Drug Interactions[M]. Sandy, Oregan:Eclectic Medical Publications, 1998.
44 Patel J, Buddha B, Dey S, et al.In vitro interaction of the HIVprotease inhibitor ritonavir with herbal constituents:changes in Pgp and CYP3A4 activity[J].Am J Ther, 2004;11:262-277.
45 Kent UM, Aviram M, Rosenblat M, et al.The licorice root derived isoflavan glabridin inhibits the activities of human levels of amitriptyline and its metabolites on comedication cytochrome P450S 3A4, 2B6, and 2C9[J].Drug Metab Dispos, 2002;30: 709-715.
46 Paolini M, Pozzetti L, Sapone A, et al.Effect of licorice and glycyrrhizin on murine liver CYP-dependent monooxygenases [J].Life Sci, 1998;62:571-582.

[1]	李珊, 柳熠鑫, 任菲菲, 李相晨, 张志清. 天然植物活性成分通过下调 P-糖蛋白逆转肿瘤多药耐药的研究进展[J]. 中国临床药理学与治疗学, 2023, 28(3): 331-340.
[2]	李智慧, 刘静彦, 邱雯, 陈红. 氟康唑胶囊在中国健康受试者的人体生物等效性研究[J]. 中国临床药理学与治疗学, 2020, 25(8): 910-915.
[3]	刘莉，彭金富，郭成贤，阳喜定，李海刚，阳国平. miR-150对药物代谢酶CYP3A4的调控作用[J]. 中国临床药理学与治疗学, 2018, 23(7): 749-754.
[4]	赵赢，张娜，庞晓丛，生立嵩，宋俊科，何兰，吕扬，杜冠华. 临床常用普伐他汀钠片大鼠体内药代动力学比较研究[J]. 中国临床药理学与治疗学, 2016, 21(6): 646-652.
[5]	朱宏平，靳高凤，陈亚军，李新华，张红，黄世博，夏春华，熊玉卿. 柚皮素对K562/A02细胞MDR1 mRNA/P gp的影响及机制研究[J]. 中国临床药理学与治疗学, 2016, 21(11): 1209-1214.
[6]	王寅声, 李晓智, 沈杰, 李絮, 温纯洁, 吴兰香, 周宏灏. 姜黄素对乳腺癌MCF-7与MCF-7/DOX细胞中P-糖蛋白表达的影响及其机制研究[J]. 中国临床药理学与治疗学, 2015, 20(7): 769-774.
[7]	黄伟, 胡晓. 细胞色素P450 3A4 代谢机制有关方面的研究进展[J]. 中国临床药理学与治疗学, 2015, 20(2): 223-229.
[8]	叶金华，靳高凤，刘名义，朱宏平，陈亚军，冯慧玲，熊玉卿. P-糖蛋白介导阿托伐他汀与阿昔莫司摄取转运的相互作用及其机制研究[J]. 中国临床药理学与治疗学, 2015, 20(12): 1392-1396.
[9]	唐霞, 辛华雯, 李维亮, 欧阳萌. 黄连素对HepG2细胞CYP3A4和P-gp的影响和作用机制研究[J]. 中国临床药理学与治疗学, 2015, 20(1): 7-13.
[10]	欧阳苍鸿, 谢娟. 例心衰患者的MDR1和CYP3A基因多态性与地高辛血药浓度的相关性研究[J]. 中国临床药理学与治疗学, 2014, 19(3): 291-296.
[11]	邹全飞, 陆榕, 樊慧蓉, 赵广荣, 张铁军, 司端运. 赛西尼在大鼠体内药代动力学和生物利用度研究[J]. 中国临床药理学与治疗学, 2014, 19(3): 254-259.
[12]	王艳, 阳国平, 郭成贤, 裴奇, 章冉冉, 黄路. 口服给药后药-时曲线双峰现象研究进展[J]. 中国临床药理学与治疗学, 2014, 19(3): 341-345.
[13]	王培培, 许杜娟, 黄灿, 徐文科, 栾家杰. 黄芪皂苷Ⅱ对人肝癌多药耐药细胞BEL-7402/FU的逆转耐药作用[J]. 中国临床药理学与治疗学, 2014, 19(2): 139-144.
[14]	王瑢, 陈珂蕊, 刘晓媚, 唐惠恩, 何震宇. 广东人群 CYP3A4基因rs28371759(20070T>C)位点多态性调查[J]. 中国临床药理学与治疗学, 2014, 19(11): 1255-1258.
[15]	田炜超, 杨瑞, 沈杰, 谢海棠, 王方杰, 肖坚. 布洛芬缓释胶囊在健康人体的相对生物利用度研究[J]. 中国临床药理学与治疗学, 2013, 18(5): 545-549.